Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography
about
An update on antibody-based immunotherapies for Clostridium difficile infectionFrizzled proteins are colonic epithelial receptors for C. difficile toxin B.Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumabBroad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.Exposure of neutralizing epitopes in the carboxyl-terminal domain of TcdB is altered by a proximal hypervariable region.Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibodyIdentification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity.Clostridium difficile Toxin A Undergoes Clathrin-Independent, PACSIN2-Dependent EndocytosisAntibody-mediated neutralization of perfringolysin o for intracellular protein delivery.Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.Nonantimicrobial drug targets for Clostridium difficile infections.Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?Bezlotoxumab: First Global Approval.Emerging monoclonal antibodies against Clostridium difficile infection.Clostridium difficile toxins A and B: Receptors, pores, and translocation into cells.Bezlotoxumab for the prevention of Clostridium difficile recurrence.Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface.Design and Purification of Subunit Vaccines for Prevention of Clostridium difficile Infection.Clostridium difficile infection in the elderly: an update on management.A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells.The role of toxins in Clostridium difficile infection.Functional defects in Clostridium difficile TcdB toxin uptake identify CSPG4 receptor-binding determinants.Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection.Treatment of recurrent Clostridium difficile colitis: a narrative review.Receptors and Binding Structures for Clostridium difficile Toxins A and B.Bezlotoxumab.The Conserved Cys-2232 in Toxin B Modulates Receptor BindingNovel Clade C-I Clostridium difficile strains escape diagnostic tests, differ in pathogenicity potential and carry toxins on extrachromosomal elements
P2860
Q26740788-EA8DAA07-34C5-46A4-99FF-76C30323FBB6Q33920445-97A0AD12-4FCA-40EA-8CC7-94B6B91C8910Q34447679-66F8C903-668C-4A12-9002-5B8E5026E6FBQ34889940-1308A733-B8E1-49BB-B562-0ACA0B448FD8Q34955629-673EF9F0-E02B-4EFA-9607-071969EC83B2Q35106011-525FB026-AFB0-4498-9425-6FD9017AE573Q35172641-CF0E8AB6-30A4-4459-9B8D-ED590917F3B6Q35545957-2282CFE1-9F53-4FC1-A15B-DABA42709E9DQ35699130-70F8D392-2DD6-47CE-8FEB-2FC46135A940Q36220118-0984EA42-ED07-4132-9E89-E85E05A80627Q36926959-07B56E9E-3E07-4A4B-B522-6A59568BED0FQ38597041-771680CF-42F8-4FD8-B67B-21F3D89151BCQ38649348-90AFA22D-A067-4035-B07D-2592833E04C5Q38668483-A7948309-F8A0-4E1B-82F9-449F9A0305ABQ38686710-2589C1A9-6857-4E78-BBFC-C21C330A6E00Q39025270-85B16702-442A-492B-978D-116EAE8C2984Q39168914-AD79F137-A520-4C08-B19D-BB57866B4FE1Q39330563-8CAD169D-134C-4DC7-82C2-90779D21D7B5Q40095035-B13B047F-B34A-4F57-B11A-8FD8D3F5AF1CQ40125340-6E93BF30-E25A-47CC-AF7E-29F4654EB22FQ40135481-D4253AF4-9091-43AC-AA19-3488B5D6D94BQ40715749-A90BA560-11CA-4515-833E-B2F244978478Q47142602-3544443B-77F7-4D68-B0DE-84BC9944E87CQ47694597-9201304C-3C8E-4DC8-BBEB-3083067D09ABQ47734724-2B81F050-5059-4289-8272-6BFB0C710397Q47903919-C60FB750-C9E4-435B-98A6-EC0646C7C53DQ49201152-5240488B-02EF-499C-9F37-1D7B73E23BB6Q50285268-AECFC357-6780-4F6C-84AD-32666590BFE5Q51662356-9C740ADB-CC06-48A6-BA90-E71F2F8E2F1BQ53762105-BDEC64CB-8154-4C00-B845-044DD7706ED8Q58707992-9F1AB45B-4703-40D2-8199-1DB67F77D4AAQ58733765-FB7B2D0D-FB24-40E6-9840-E57B9273990E
P2860
Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mechanism of Action and Epitop ...... ealed by X-ray Crystallography
@ast
Mechanism of Action and Epitop ...... ealed by X-ray Crystallography
@en
Mechanism of Action and Epitop ...... ealed by X-ray Crystallography
@nl
type
label
Mechanism of Action and Epitop ...... ealed by X-ray Crystallography
@ast
Mechanism of Action and Epitop ...... ealed by X-ray Crystallography
@en
Mechanism of Action and Epitop ...... ealed by X-ray Crystallography
@nl
prefLabel
Mechanism of Action and Epitop ...... ealed by X-ray Crystallography
@ast
Mechanism of Action and Epitop ...... ealed by X-ray Crystallography
@en
Mechanism of Action and Epitop ...... ealed by X-ray Crystallography
@nl
P2093
P2860
P921
P3181
P356
P1476
Mechanism of Action and Epitop ...... ealed by X-ray Crystallography
@en
P2093
Alex G Therien
Edward DiNunzio
Fred Racine
Grigori Ermakov
Jerzy Karczewski
Lorraine D Hernandez
Maribel Beaumont
Nicholas Murgolo
Paul Reichert
P2860
P304
P3181
P356
10.1074/JBC.M114.560748
P407
P577
2014-06-27T00:00:00Z